☆ 4.6 Article

Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study

BMJ OPEN (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Infectious Diseases

Diabetes mellitus and TB - finding strategies to reduce the double burden of disease

L. Davies Forsman et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2023)

Add to Collection

Article Infectious Diseases

Towards clinical breakpoints for non-tuberculous mycobacteria-Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution

Gabrielle Froberg et al.

Summary: The study evaluated the minimum inhibitory concentration (MIC) distributions of non-tuberculous mycobacteria (NTM) to establish antimicrobial susceptibility testing (AST) breakpoints. MIC distributions for drugs against Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) were collected from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined, highlighting the need for further method refinement in establishing clinical breakpoints for NTM.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Add to Collection

Article Respiratory System

Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China

Xubin Zheng et al.

Summary: This study investigated the impact of drug exposure and susceptibility on treatment response of multidrug-resistant tuberculosis (MDR-TB). The researchers found that target attainment of TB drugs was associated with treatment response, and identified potential target thresholds for early dose adjustment.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Infectious Diseases

Clinical standards for the dosing and management of TB drugs

J. W. C. Alffenaar et al.

Summary: This article presents clinical standards for dosing and management of TB drugs, aiming to guide clinicians and program managers in planning and implementing locally appropriate measures for optimal treatment and improved patient care.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2022)

Add to Collection

Article Immunology

Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response

Xubin Zheng et al.

Summary: This study aimed to identify clinically relevant PK/PD thresholds for tuberculosis treatment optimization. Using CART analysis and LASSO logistic regression, the study found that AUC/MIC values and drug exposure of TB drugs were associated with clinical outcomes and adverse events. Further research is needed to explore the impact of CART-derived thresholds for individualized dosing on treatment outcomes in randomized controlled trials.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Pharmacology & Pharmacy

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

Marieke G. G. Sturkenboom et al.

Summary: Tuberculosis remains the leading cause of death from infectious diseases, with the pharmacokinetics and pharmacodynamics of anti-TB drugs playing a crucial role in treatment optimization. Population pharmacokinetic models and Bayesian dose adjustment can be utilized to optimize treatment and prevent slow response, acquired drug resistance, and adverse effects. The development of therapeutic drug monitoring for TB relies on academic and clinical collaborations for future advancements in this field.

CLINICAL PHARMACOKINETICS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections

Jan-Willem Alffenaar et al.

Summary: Nontuberculous mycobacteria can cause a range of infections, from mild to life-threatening. The complexity of treatment, potential resistance, toxicity, and high failure rate make therapy difficult. Therapeutic drug monitoring may help optimize treatment, but guidance for this condition is currently limited.

CLINICAL PHARMACOKINETICS (2021)

Add to Collection

Article Infectious Diseases

Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study

Yaoju Tan et al.

Summary: Approximately one-fifteenth of smear-positive patients with symptoms suggestive of pulmonary tuberculosis in China are afflicted with nontuberculous mycobacterial pulmonary diseases. There is significant geographic diversity in the prevalence of NTM-PD across different regions. NTM-PD patients tend to exhibit less severe clinical symptoms compared to PTB patients.

JOURNAL OF INFECTION (2021)

Add to Collection

Article Immunology

Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009-2014

Emily E. Ricotta et al.

Summary: NTM causes pulmonary and extrapulmonary infections in susceptible individuals in the United States. The prevalence of NTM infections varies by geographic region, with rapidly growing NTM being most prevalent in southern states. Infection with Mycobacterium avium complex is more common in patients with concurrent HIV and fungal infections, which has implications for treatment effectiveness.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Respiratory System

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

Charles L. Daley et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection

Article Respiratory System

Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large US Managed Care Health Plan, 2008-2015

Kevin L. Winthrop et al.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)

Add to Collection

Letter Respiratory System

Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease

Seong Mi Moon et al.

EUROPEAN RESPIRATORY JOURNAL (2019)

Add to Collection

Article Microbiology

Rapid Identification of Clinically Relevant Mycobacterium Species by Multicolor Melting Curve Analysis

Ye Xu et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2019)

Add to Collection

Article Immunology

Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007-2016

Hyewon Lee et al.

EMERGING INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

MIC-based dose adjustment: facts and fables

Johan W. Mouton et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)

Add to Collection

Review Critical Care Medicine

Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease A Systematic Review

Roland Diel et al.

CHEST (2018)

Add to Collection

Editorial Material Respiratory System

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

Jakko van Ingen et al.

EUROPEAN RESPIRATORY JOURNAL (2018)

Add to Collection

Article Infectious Diseases

Linezolid as treatment for pulmonary Mycobacterium avium disease

Devyani Deshpande et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)

Add to Collection

Article Infectious Diseases

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

Devyani Deshpande et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)

Add to Collection

Article Immunology

Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis

Nakwon Kwak et al.

CLINICAL INFECTIOUS DISEASES (2017)

Add to Collection

Article Pharmacology & Pharmacy

Defining the Optimal Dose of Rifapentine for Pulmonary Tuberculosis: Exposure-Response Relations From Two Phase II Clinical Trials

R. M. Savic et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Article Microbiology

Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease

Byeong-Ho Jeong et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Critical Care Medicine

Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease

Hye Yun Park et al.

CHEST (2016)

Add to Collection

Article Immunology

Prevalence of Nontuberculous Mycobacterial Pulmonary Disease, Germany, 2009-2014

Felix C. Ringshausen et al.

EMERGING INFECTIOUS DISEASES (2016)

Add to Collection

Letter Immunology

Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan

Ho Namkoong et al.

EMERGING INFECTIOUS DISEASES (2016)

Add to Collection

Article Respiratory System

Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection A Prospective Cohort Study

Christopher A. Czaja et al.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)

Add to Collection

Article Critical Care Medicine

Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease

David E. Griffith et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

Abdullah Alsultan et al.

DRUGS (2014)

Add to Collection

Correction Microbiology

In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates (vol 51, pg 3389, 2013)

Barbara A. Brown-Elliott et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2014)

Add to Collection

Article Infectious Diseases

Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections

C. Magis-Escurra et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)

Add to Collection

Article Critical Care Medicine

The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment

Jakko van Ingen et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)

Add to Collection

Article Critical Care Medicine

Therapeutic Drug Monitoring in the Treatment of Mycobacterium avium Complex Lung Disease

Won-Jung Koh et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)

Add to Collection

Article Infectious Diseases

Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents

A. H. Diacon et al.

CLINICAL MICROBIOLOGY AND INFECTION (2012)

Add to Collection

Article Microbiology

Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

Devyani Deshpande et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

Add to Collection

Article Microbiology

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

Devyani Deshpande et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.